Another Prempro judgment, another appeal. An Arkansas jury yesterday ordered Wyeth and Upjohn to pay more than $27 million in punitive damages; that would allocate out to $19.4 million from Wyeth and $7.8 million from Upjohn, a Pfizer unit. That's on top of $2.75 million in compensatory damages. The jury found that the plaintiff developed breast cancer from taking the companies' hormone-replacement therapies.
By late afternoon, Wyeth had announced it plans to appeal the jury verdicts. "There is no basis in fact or law for this award...We will pursue several post-trial motions and will ultimately appeal the entire case if necessary," Wyeth's lawyer said.
Meanwhile, Wyeth is also appealing a Nevada court's ruling in a similar hormone-replacement case. A jury awarded three women $134 million in the case; though the judge then cut that award to $58 million, the company filed an appeal, saying that the verdict itself was "irreparably flawed and fraught with error." The company faces thousands of other hormone-replacement cases across the country.
Court dismisses lawsuit on Wyeth's Prempro. Report
Jury fines Wyeth $134.5M in hormone suit. Report
Wyeth asks judge to cut $134M award. Report